Mr. Speaker, I yield such time as he may consume to the gentleman from Louisiana (Mr. Boustany), a member of the Education and Labor Committee. Mr. Speaker, I yield myself 3 minutes. Obviously I rise in strong support of H.R. 493. I think…
Mr. Speaker, I yield such time as he may consume to the gentleman from Louisiana (Mr. Boustany), a member of the Education and Labor Committee.
Mr. Speaker, I yield myself 3 minutes.
Obviously I rise in strong support of H.R. 493. I think it has been an honor to work with the gentlewoman from New York (Ms. Slaughter) and, I might add, work we did.
When the Human Genome Project was completed in 2003, the House of Representatives recognized it as ``one of the most significant scientific accomplishments of the past 100 years.''
For the first time, individuals actually could know their genetic risk of developing disorders such as cancer, diabetes, heart disease, Parkinson's, Alzheimer's, and they could take preventative measures to decrease their risks. It spawned a personalized medicine movement, focusing on catching diseases earlier, when they are cheaper and easier to treat or, even better, preventing the onset of the disease in the first place.
But after investing more than $3.7 billion in taxpayer money to achieve this breakthrough, Congress walked away and left the job unfinished.
We left people without any assurance that their genetic information would not be used against them. So, understandably, they avoided this great technology, never realizing the untold health benefits and savings.
This concern even spilled over into NIH, where a fear of genetic discrimination is currently the most commonly cited reason for not participating in research on potentially lifesaving genetic testing for breast cancer and colon cancer. Fully one-third of those eligible to participate declined to do so for this reason, undermining the development of new treatments and cures.
Mr. Speaker, today Congress is here to settle some unfinished business and provide Americans the protections against genetic discrimination in health care insurance and employment that they need to utilize genetic testing without fear.
Besides the more than 200 health advocacy and business organizations that support this bill, recent surveys show 93 percent of Americans believe that employers and insurers should not be able to use genetic information to discriminate.
With numbers like this, it should come as no surprise that this legislation enjoys overwhelmingly bipartisan support. And I want to take a moment to thank my good friend Ms. Slaughter, Mr. Walden and Ms. Eshoo. It truly has been a pleasure working with all of them. I would also like to thank Mr. McKeon, Mr. Miller and all the other chairmen and ranking full committee and subcommittee members for working together to make this a better bill.
I would be remiss if I did not mention the members of the Coalition for Genetic Fairness, without whom this bill would not be possible.
Finally, I would like to thank Brian Petersen of my staff and Michelle Adams of Ms. Slaughter's staff and all the outstanding staff who worked tirelessly behind the scenes on our behalf and who have put in long hours on this legislation.
Why must we pass this bill today? Because it dramatically reduces health care costs while saving or extending human lives.
Madam Speaker, I reserve the balance of my time.
Madam Speaker, I yield 3\1/2\ minutes to the gentleman from Florida (Mr. Stearns).
(Mr. STEARNS asked and was given permission to revise and extend his remarks.)
Madam Speaker, may I inquire how much time remains on both sides?
Madam Speaker, I yield 2 minutes to a member of the Energy and Commerce Committee, Dr. Burgess.
Madam Speaker, I yield myself 1 minute.
Madam Speaker, I think that by incorporating genetic testing, we can significantly reduce the cost of chronic disease, which currently accounts for 70 cents of every health care dollar. I think the President of the United States understands this, and I will include for the Record the statement of administrative policy from the White House in favor of this legislation.
Executive Office of the President, Office of Management
and Budget,
Washington, DC, April 25, 2007.
Statement of Administration Policy
H.R. 493--Genetic Information Nondiscrimination Act of 2007 (Rep.
Slaughter (D) NY and 224 cosponsors)
The Administration favors enactment of legislation to
prohibit the improper use of genetic information in health
insurance and employment. The Administration supports House
passage of H.R. 493, which would prohibit group health plans
and health insurers from denying coverage to a healthy
individual or charging that person higher premiums based
solely on a genetic prediposition to developing a disease in
the future. The legislation also would bar employers from
using individuals' genetic information when making hiring,
firing, job placement, or promotion decisions. The
Administration appreciates that the House bill clarifies that
the bill's protections cover unborn children.
The mapping of the human genome has led to more information
about diseases and a better understanding of our genetic
code. Scientists are pursuing new diagnostics, treatments,
and cures based on this information, but the potential misuse
of this information raises serious moral and legal issues.
Concern about unwarranted use of genetic information
threatens the utilization of existing genetic tests as well
as the ability to conduct further research. The
Administration wants to work with Congress to further perfect
this legislation and to make genetic discrimination illegal
and provide individuals with fair, reasonable protections
against improper use of their genetic information.
Madam Speaker, I reserve the balance of my time.
Madam Speaker, I reserve the balance of my time.
Madam Speaker, I have no further speakers, so I will yield myself the balance of my time to close.
Madam Speaker, this bill has been a bipartisan bill. It has got 95 Republicans and 125 Democrats. GINA passed the Education and Labor Committee, Energy and Commerce Committee and the Ways and Means Committee by voice vote. I think that GINA is needed to maintain high- quality genetic research and clinical trials at NIH. It passed the Senate last year 98-0, and the last Congress was a strong SAP for them, so when this goes to conference we will see what happens this year.
Let me just say that Newt Gingrich said to not have this bill is to cripple our ability to save lives. I would like to enter into the Record a statement of his in the Washington Times, and just to quote a little bit from it.
``Without protection from genetic discrimination, we risk missing out on the promise of personalized medicine. But if we apply time-honored principles of fairness and justice to the genome era, we can grant the American public the gift of better informed patients, better equipped providers, an enhanced biotech industry, improved health and lives saved.
``Let's not withhold this gift any longer. Let's empower all Americans to embrace the possibilities of personalized medicine for better health, and let's commend the forward-thinking bipartisanship of the 110th Congress that has brought us to the threshold of a world where Americans can embrace personalized medicine without fear.
``Our health, and that of our children and grandchildren, depends on it.''
Let me just say that this bill had to go through three committees, and that is not easy, Education and Labor, Ways and Means and the Energy and Commerce. That is no small feat. I really thank Chairman Slaughter for all that she did to make sure that this went through, and all the time she has spent on this. It has been a great honor to work with her.
Again, let me thank the chairmen of these committees and the ranking members for the time that they put in, and all the Members that came down to speak today and all the Members that supported this as cosponsors.
To go through the three committees, everybody knows something about this place, but everybody wants to put their stamp on it. To come out with a bill we can all agree on, and, as people said, they have some things they would still like to put in, but I think being able to manage all of the different committees, and what was their jurisdiction and what maybe they thought was their jurisdiction but really was the jurisdiction of another committee, makes it a very interesting process.
And I think we all learned about how this type of bill works. It is a very technical bill, and that is why we thank all of the 200 groups, at least 200 groups that have worked on this bill and been able to give us the technical information that we needed to make this something that is going to save lives. It is going to lower costs and it also is going to find the cures for so many of these diseases and disorders, because people will be willing to go into clinical trials. So I congratulate all of the people that participated.
Madam Speaker, I include the article by Newt Gingrich for the Record
Congress of the United States,
Washington, DC.
Why does Newt Gingrich Support GINA?
Dear Republican Colleague, We wanted to draw your attention
to this op-ed by Newt Gingrich supporting H.R. 493, the
Genetic Information Nondiscrimination Act. It appeared in the
Washington Times on April 11, 2007. We urge you to vote
``yes'' when this legislation comes to the floor.
Sincerely,
Judy Biggert,
Member of Congress.